Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2019 to Jul 2024
Aastrom Biosciences, Inc. Added to Russell 3000 Index
ANN ARBOR, Mich., June 28 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc.
(NASDAQ:ASTM) announced today that it was added to the Russell 3000(R) Index
effective at the close of market on Friday, June 24, 2005. The Russell 3000
Index measures the performance of the 3,000 largest U.S. companies based on
total market capitalization.
Membership in the Russell 3000, which remains in place for one year, means
automatic inclusion in other Russell indexes. Russell determines membership
for its equity indexes primarily by objective market capitalization rankings.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for investment strategies.
Investment managers who oversee Russell's funds purchase shares of member
stocks according to each company's weighting in a particular index.
About Russell
Russell, a global leader in multi-manager investment services, provides
investment products and services in more than 39 countries. Russell manages
more than $135 billion in assets and advises clients worldwide representing
$2.3 trillion. Founded in 1936, Russell is a subsidiary of Northwestern Mutual
and is headquartered in Tacoma, Wash., with additional offices in New York,
Toronto, London, Paris, Singapore, Sydney, Auckland and Tokyo. For more
information, go to http://www.russell.com/.
About Aastrom Biosciences, Inc.
Aastrom Biosciences, Inc. (NASDAQ:ASTM) is developing patient-specific products
for the repair or regeneration of human tissues, utilizing the Company's
proprietary adult stem cell technology. Aastrom's strategic position in the
tissue regeneration sector is enabled by its proprietary Tissue Repair Cells
(TRCs), a mix of bone marrow-derived adult stem and progenitor cells, and the
AastromReplicell(R) System, an industry-unique automated cell production
platform used to produce cells for clinical use. TRCs are the core component of
the products Aastrom is developing for severe bone fractures, ischemic vascular
disease, jaw reconstruction and spine fusion, with Phase I/II level clinical
trials active in the U.S. and EU for some of these indications.
For more information, visit Aastrom's website at http://www.aastrom.com/.
This document contains forward-looking statements, including without
limitation, statements concerning planned clinical trials, product development
objectives, potential product applications, and potential advantages of Tissue
Repair Cells (TRCs) and the AastromReplicell(R) System, which involve certain
risks and uncertainties. The forward-looking statements are also identified
through use of the word "plan," and other words of similar meaning. Actual
results may differ significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in differences
are clinical trial results, potential product development difficulties, the
effects of competitive therapies, regulatory approval requirements, the
availability of financial and other resources and the allocation of resources
among different potential uses. These and other significant factors are
discussed in greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission.
CONTACTS:
Kris M. Maly or Cameron Associates
Becky Anderson Kevin McGrath -- Institutions
Investor Relations Department Phone: (212) 245-4577
Aastrom Biosciences, Inc. Alyson Nikulicz -- Media
Phone: (734) 930-5777 Phone: (212) 554-5464
DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly or Becky Anderson, Investor Relations Department
of Aastrom Biosciences, Inc., +1-734-930-5777; or Kevin McGrath, Institutions,
+1-212-245-4577, or Alyson Nikulicz, Media, +1-212-554-5464
Web site: http://www.aastrom.com/
http://www.russell.com/